Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

patient organisations

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

- PMLiVE

OPEN Health CSR Report 2019

Margot Hannah, Partner and Group Managing Director, and CSR lead at OPEN Health shares her thoughts on our latest report.

OPEN Health

- PMLiVE

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial

- PMLiVE

Policy and public health: all the decisions we can’t see

January was a bad month for healthcare in China

- PMLiVE

Lundbeck gets US approval for migraine drug at heart of Alder takeover

US regulator clears CGRP inhibitor under Vyepti trade name

- PMLiVE

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Continues to bulk up its pipeline

- PMLiVE

Lundbeck’s key products shine in Q2 but problems remain

Faces increasing patent losses

- PMLiVE

Lundbeck snaps up Abide Therapeutics for $400m

Also acquires its lead drug for Tourette’s syndrome

- PMLiVE

GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

Company seeking to revive lacklustre marketing performance

- PMLiVE

Transparency and accountability: tackling opacity and blame head-on

Let’s be honest, big pharma lacks trust and many love to hate it. Faceless corporations tainted by past own-goals, profiteering, cherry-picked data and spun claims - so goes the lazy...

- PMLiVE

Is trust in healthcare improving?

Edelman’s Annual Trust Barometer for 2017 painted a sobering picture of trust around the globe with a collapse in trust in all four of the major institutions studied - business,...

- PMLiVE

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links